DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993 - Rapid Response Partnership Vehicle
Notice is hereby given that, on April 12, 2024,
pursuant to section 6(a) of the National Cooperative
Research and Production Act of 1993, 15 U.S.C. 4301 et seq.
(“the Act”), Rapid Response Partnership Vehicle (“RRPV”)
has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission
disclosing changes in its membership.

The notifications

were filed for the purpose of extending the Act’s
provisions limiting the recovery of antitrust plaintiffs to
actual damages under specified circumstances.
Specifically, A-line, Inc., Signal Hill, CA; ANP
Technologies, Inc., Newark, DE; ARNAV Biotech Corp.,
Atlanta, GA; Action Medical Technologies LLC, Conshohocken,
PA; AmerStem, Inc., Camarillo, CA; American Type Culture
Collection, Manassas, VA; Aposense, Ltd., Petach Tikva,
ISRAEL; Appili Therapeutics USA, Inc., Frederick, MD;
Aptitude Medical Systems, Goleta, CA; Arranta Bio MA LLC,
Watertown, MA; Asha Therapeutics LLC, Tampa, FL; BDO Public
Sector LLC, Mclean, VA; BRCR Medical Center, Inc.,
Plantation, FL; Battelle Memorial Institute, Columbus, OH;
BioInfoExperts LLC, Thibodaux, LA; Boost Biopharma, Inc.,
Amherst, MA; Bracane Company, Plano, TX; Capra Biosciences,

Inc., Manassas, VA; Capricor Therapeutics, Inc., San Diego,
CA; CellCarta Biosciences, Inc., Montreal, CANADA; Cerba
Research USA, Inc., Lake Success, NY; Clarametyx
Biosciences, Inc., Columbus, OH; Clarus Biologics, Inc.,
Chapel Hill, NC; Cue Health, Inc., San Diego, CA; D'Angelo
Technologies LLC, Beavercreek, OH; DEKA Research &
Development Corp., Manchester, NH; Datavant, Phoenix, AZ;
Deutsches Zentrum für Infektionsforschung e.V.,
Braunschweig, GERMANY; Diagnostic Consulting Network LLC
dba DCN Diagnostics, Carlsbad, CA; Diasorin Molecular,
Cypress, CA; EMD Millipore dba MilliporeSigma, Burlington,
MA; Ethris GmbH, Planegg, GERMANY; FONDAZIONE BIOTECNOPOLO
DI SIENA, SIENA, ITALY; Flagship Labs, Cambridge, MA; Fred
Hutchinson Cancer Center, Seattle, WA; Genentech, South San
Francisco, CA; GiwoTech, Inc., Wilmington, DE; Global
Action Alliance, Inc., Ashburn, VA; HDT Bio Corp., Seattle,
WA; Hope Biosciences, Sugar Land, TX; IQVIA Government
Solutions, Inc., Falls Church, VA; Icahn School of Medicine
at Mount Sinai, New York, NY; InBios International,
Seattle, WA; Injection Safety Industries LLC, Bowling
Green, KY; Inovio Pharmaceuticals, Plymouth Meeting, PA;
Integrated Biotherapeutics LLC dba IBT Bioservices,
Rockville, MD; LTS Lohmann Therapie-Systeme AG, Andernach,
GERMANY; Labcorp, Burlington, NC; Labcorp-Monogram
Biosciences, South San Francisco, CA; Lyndra Therapeutics,
Inc., Watertown, MA; Major, Inc., Los Angeles, CA; MalarVx,

Inc., Seattle, WA; Mirimus, Inc., Brooklyn, NY; Nature's
Toolbox, Inc., Rio Rancho, NM; New Horizon Biotech, Inc.,
Nazareth, PA; OncoC4, Inc., Rockville, MD; PIF Partners
LLC, Englewood, NJ; PharmaJet, Inc., Golden, CO; Precision
for Medicine, Inc., Frederick, MD; Revvity Health Sciences,
Hopkinton, MA; Rocketvax, Ltd., Basel, SWITZERLAND; Selva
Therapeutics, Inc., San Mateo, CA; Sentio BioSciences LLC,
Maryland Heights, MO; Solaris Vaccines, Inc., Fort Collins,
CO; Spring Discovery, Inc., San Carlos, CA; Technical
Resources International, Inc., Bethesda, MD; The Emmes
Company LLC, Rockville, MD; The Pandemic Institute (Legally
hosted by the University of Liverpool), Liverpool, UNITED
KINGDOM; Tonix Pharmaceutical Holdings, Chatham, NJ;
Trawsfynydd Therapeutics, Inc., Rockville, MD; US Specialty
Formulations LLC, Allentown, PA; Univercells S.A.,
Brussels, BELGIUM; VaxForm LLC, Bethlehem, PA; VisMederi
Srl, Siena, ITALY; Vyriad, Inc., Rochester, MN; Walgreen
Co., Deerfield, IL; Yourbio Health, Medford, MA; and
iosBio, Ltd., Haywards Heath, UNITED KINGDOM, have been
added as parties to this venture.
No other changes have been made in either the
membership or planned activity of the group research
project.

Membership in this group research project remains

open, and RRPV intends to file additional written
notifications disclosing all changes in membership.

On January 5, 2024, RRPV filed its original
notification pursuant to section 6(a) of the Act. The
Department of Justice published a notice in the Federal
Register pursuant to section 6(b) of the Act on April 16,
2024 (89 FR 26928).
Suzanne Morris,
Deputy Director Civil Enforcement Operations,
Antitrust Division.

[FR Doc. 2024-13625 Filed: 6/20/2024 8:45 am; Publication Date: 6/21/2024]